ChallengingCases by MedCases

Go back to:

New Directions in the Management of Ischemic Heart Disease:
Thinking Outside the Heart-Shaped Box

Request for Credit

Omni Hotel, Atlanta, Georgia
March 15, 2010

To Receive Credit:

Please scroll through this page to read all the disclosures and important information. Then click on the button at the bottom to proceed to the credit request page.

Course Description

The American Heart Association estimates that of 16.8 million patients with coronary artery disease (CAD), 9.8 million patients have chronic stable angina secondary to ischemic heart disease, with 500,000 new cases presenting annually. Epidemiologic data also show that approximately 10% of the population older than 65 years is affected, with a greater prevalence rate among women. However, despite recent diagnostic and therapeutic advances, long-term patient outcomes are disappointing. The fundamentally systemic nature of CAD and its associated manifestations, including ischemic heart disease, results in particularly complex and challenging therapeutic needs. Clinicians must continue to enhance their expertise in managing these challenges as new evidence becomes available and professional guidelines are updated.

Important new evidence regarding appropriate stratification of patients between optimized medical therapy and interventional strategies needs to be implemented to avoid the unnecessary expense and complications of an intervention that does not improve patient outcomes or quality of life. With medical therapy, optimizing therapeutic regimens by considering the evidence and significant nuances in the use of novel and conventional agents, alone or in combination, is essential to improving outcomes. In addition, appropriate strategies need to be assessed individually in different patient settings, especially in the context of certain special populations and comorbid conditions. Even when all such factors have been considered and optimal strategies have been carefully selected and implemented, patients with poor therapeutic compliance and residual or intractable symptoms complicate this field. Such challenges and complexities will have to be overcome if patients are to achieve maximal control of symptoms and better prevention of further complications of their ischemic heart disease.

This 2-hour educational symposium addresses these challenges and complexities. You and the expert faculty will discuss 2 interesting and challenging patient cases in a collaborative, stimulating, and interactive manner. The case discussions will be facilitated by the innovative MedCases format, CaseRoom.

Course Objectives

After participating in this activity, you should be able to:

Discuss the practical considerations and application of emerging evidence in the stratification of patients towards optimal medical management and/or interventional therapy

Describe the therapeutic options for chronic stable angina, including the role of conventional as well as novel antianginal agents

Illustrate how optimal medical strategies can be implemented to improve patient outcomes effectively

Identify treatment gaps in special populations and in the context of comorbid conditions, such as post revascularization patients or patients with impaired left ventricular function, ischemic cardiomyopathy with HF, and diabetes


	Follow us on Twitter Author Cases For Us

Disclosures and Important Information

Supported by an independent educational grant from Gilead Sciences Medical Affairs.

This event is not part of the official ACC Annual Scientific Session and/or the ACC's Innovation in Intervention: i2 Summit in Partnership wit the Cardiovascular Research Foundation, as planned by their Program Committees.

Faculty

Associate Professor of Medicine
Harvard Medical School
Co-Director, Samuel A. Levine Cardiac Unit, BWH
Brigham and Women’s Hospital
Boston, MA

Associate Professor of Medicine
Harvard Medical School
Director, Samuel A. Levine Cardiac Unit
Cardiovascular Divison/TIMI Study Group
Associate Physician
Division of Cardiac Medicine
Brigham and Women’s Hospital
Boston, MA

Professor of Medicine
University of Pennsylvania School of Medicine
Director, Interventional Cardiac Research
Penn Heart and Vascular Center
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure Statement

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is MedCases policy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The following was reported:

Peter H. Stone, MD has indicated that he has received honorarium from Millennium Pharmaceuticals.

David A. Morrow, MD, MPH has indicated that he has received grants for clinical research and educational activities from: Accumetrics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Beckman Coulter, Bristol-Myers Squibb Company, Gilead Sciences, Daiichi Sankyo, Inc., Eli Lilly and Company, Genentech, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Merck & Co, Inc., Nanosphere, Inc, Novartis Pharmaceuticals Corporation, OrthoClinical Diagnostics, Pfizer Inc, Roche Diagnostics, sanofi-aventis, Siemens Medical Solutions, Singulex, and Schering-Plough; served as an advisor or consultant to AstraZeneca Pharmaceuticals LP, Beckman Coulter, CardioKinetix, Gilead Sciences, Ikaria, Menarini, Molecular Insight, OrthoClinical Diagnostics, sanofi-aventis, Schering-Plough Research Institute, Siemens Medical Solutions, and Roche Diagnostics (uncompensated); and received honoraria from Gilead Sciences and Eli Lilly and Co.

Robert L. Wilensky, MD has indicated that he has not received financial support for consultation, research, or evaluation, or have a financial interest relevant to this activity.

Accreditation Statement

MedCases, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education.

Credit Designation Statement

MedCases designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

For Further Information

MedCases
4365 US Highway 1, Suite 207
Princeton, NJ 08540
Phone (609) 454-0679
Fax (609) 951-0112
cme@medcases.com

Request Credit